Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Alemtuzumab is an anti CD52 monoclonal antibody. The CD52 antigen is present at the surface
of B,T NK lymphocytes. It is expressed at various levels at the surface of ALL blast cells.
Adult patients with ALL in relapse have less than 10% probability of long term survival. The
present study will test the response rate (partial and complete remission) of refractory ALL
or ALL in relapse. It is hoped that if a CR can be achieved, further consideration will be
given for a hematopoietic stem cell transplant.
The use of G-CSF is justified by a possible increase in ADCC.